News

September 2, 2015 9:45 am
Bristol-Myers Squibb Company and AbbVie today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for Empliciti (elotuzumab), an investigational Signaling Lymphocyte...
September 2, 2015 9:30 am
Reports in two highly respected medical journals—the Lancet and the New England Journal of Medicine—agree that weed killers used with genetically modified crops (commonly known as GMOs), such as corn and soybeans, cause cancer. In his blog this...
August 25, 2015 10:00 am
In his blog this week, IMF Chariman Dr. Brian Durie compares two opinions on the value of precision medicine as outlined in recent articles in Science and The New England Journal of Medicine. Although precision medicine is popular and ultimately...
August 25, 2015 10:00 am
Selinexor is an orally administered Selective Inhibitor of Nuclear Export, or SINE™, therapy for the treatment of multiple myeloma. Selinexor inhibits the transport of tumor suppressor proteins from the cell nucleus, where they detect cancerous DNA...

Pages